EBITDA Margin % is calculated as EBITDA divided by its Revenue. Linical Co's EBITDA for the
six
months ended in Mar. 2026 was 円-2,197 Mil. Linical Co's Revenue for the
six
months ended in Mar. 2026 was 円3,806 Mil. Therefore, Linical Co's EBITDA margin for the quarter that ended in Mar. 2026 was -57.72%.
Linical Co (TSE:2183) EBITDA Margin % Explanation
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Linical Co EBITDA Margin % Related Terms
Linical Co EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for Linical Co's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TSE:2183 vs VRTX, REGN, ALNY: EBITDA Margin % Comparison
For the Biotechnology subindustry, Linical Co's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Linical Co EBITDA Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Linical Co's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Linical Co's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Linical Co (TSE:2183) has a EBITDA Margin % of -57.72% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Linical Co and its competitors. According to the industry distribution chart, Linical Co ranks #408 out of 944 companies in the Biotechnology industry, placing it in the top 43.2%.
Is Linical Co's EBITDA Margin % too high?
Linical Co's current EBITDA Margin % is -57.72%. Based on the distribution chart, Linical Co ranks #408 out of 944 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Linical Co has a GF Score™ of 48/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Linical Co's EBITDA Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Linical Co ranks #408 out of 944 companies for EBITDA Margin %. This puts Linical Co in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Biotechnology company?
A good EBITDA Margin % depends on the Biotechnology industry context. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Linical Co and its competitors. Linical Co's current EBITDA Margin % is -57.72%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Linical Co stock overvalued right now?
Based on GuruFocus' analysis, Linical Co (TSE:2183) is currently considered Possible Value Trap. The stock's GF Value™ is 円310.47, compared to a current price of 円202.00 — trading 34.9% below its estimated fair value. The current EBITDA Margin % is -57.72%. Linical Co's overall GF Score™ is 48/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Linical Co (TSE:2183), the current EBITDA Margin % is -57.72% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Linical Co (TSE:2183) Overvalued in 2026?
Based on GuruFocus' analysis, Linical Co stock appears to be undervalued.
The current stock price of 円202.00 is trading 34.9% below its estimated GF Value™ of 円310.47.
GuruFocus considers Linical Co to be Possible Value Trap.
Key valuation signals for TSE:2183:
EBITDA Margin %: -57.72%
GF Value™: 円310.47 vs. price of 円202.00 (34.9% below fair value)
No single metric tells the full story. See the TSE:2183 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSE:2183 has been successfully added to your 
